Cargando…

Oritavancin for the treatment of complicated gram-positive infection in persons who inject drugs

BACKGROUND: Treatment of complicated infections in persons who inject drugs (PWID) and patients experiencing homelessness poses a unique challenge to clinicians. Long-acting lipoglycopeptide antibiotics, such as oritavancin, may facilitate extended courses of outpatient intravenous therapy while avo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Ahiskali, Aileen, Rhodes, Heather
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7594421/ https://www.ncbi.nlm.nih.gov/pubmed/33115540 http://dx.doi.org/10.1186/s40360-020-00452-z

Ejemplares similares

1553. Efficacy and Safety of Dalbavancin and Oritavancin in the Treatment of Gram-Positive Infections
por: Brown, Vanessa, et al.
Publicado: (2020)

Oritavancin: A New Lipoglycopeptide Antibiotic in the Treatment of Gram-Positive Infections
por: Brade, Karrine D., et al.
Publicado: (2016)

Real-World Evidence for Oritavancin Use in Gram-Positive Infections
Publicado: (2020)

Oritavancin vs Standard of Care for Treatment of Nonendovascular Gram-Positive Bloodstream Infections
por: Moenster, Ryan P, et al.
Publicado: (2023)

Real-World Experience with Oritavancin Therapy in Invasive Gram-Positive Infections
por: Stewart, Cassie L., et al.
Publicado: (2017)

1845. Oritavancin Compared to the Standard-of-Care for the Treatment of Gram-positive Blood Stream Infections
por: Moenster, Ryan P, et al.
Publicado: (2022)

The CHROME Study, a Real-world Experience of Single- and Multiple-Dose Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

443. The CHROME Study, a Real-World Experiential Registry of the Use of Oritavancin for Treatment of Gram-Positive Infections
por: Redell, Mark, et al.
Publicado: (2019)

Clinical Outcomes and Economic Impact of Oritavancin for Gram-Positive Infections: A Single Academic Medical Center Health System Experience
por: Brownell, Lauren E., et al.
Publicado: (2020)

2266. Microbiology and Predictors of Gram-Negative Infections in Persons Who Inject Drugs with Injection-Related Infections Requiring Hospitalization
por: Mulbah, Jessica L, et al.
Publicado: (2023)

Real-World Evidence Studies of Oritavancin Use in Gram-Positive Infections Augment Randomized Controlled Trials to Address Clinical and Economic Outcomes
por: Redell, Mark
Publicado: (2020)

Activity of Oritavancin against Gram-Positive Pathogens Causing Bloodstream Infections in the United States over 10 Years: Focus on Drug-Resistant Enterococcal Subsets (2010–2019)
por: Carvalhaes, Cecilia G., et al.
Publicado: (2022)

470 Oritavancin Activity Against Gram-positive Clinical Isolates Responsible for Documented Skin and Skin Structure Infections in USA and European Hospitals (2012-2013)
por: Mendes, Rodrigo E., et al.
Publicado: (2014)

Real-World Use of Oritavancin for the Treatment of Osteomyelitis
por: Scoble, Patrick J., et al.
Publicado: (2020)

Analysis of Oritavancin Activity against Gram-Positive Clinical Isolates Responsible for Bacterial Endocarditis in United States and European Hospitals (2008–2016)
por: Pfaller, Michael A, et al.
Publicado: (2017)

Profile of oritavancin and its potential in the treatment of acute bacterial skin structure infections
por: Mitra, Subhashis, et al.
Publicado: (2015)

1420. Successful Treatment of Acute Osteomyelitis with Once-Weekly Oritavancin
por: Van Hise, Nicholas W, et al.
Publicado: (2019)

Oritavancin for the treatment of acute bacterial skin and skin structure infections: an evidence-based review
por: Kmeid, Joumana, et al.
Publicado: (2015)

1583. Eight Years of Sustained Potency and Activity of Oritavancin against Gram-Positive Isolates Causing Bacteremia and Endocarditis in the USA, Including Enterococcal Infections Requiring an Optimized Dosing Strategy for Daptomycin
por: Carvalhaes, Cecilia G, et al.
Publicado: (2019)

Risk factors of infective endocarditis in persons who inject drugs
por: Shah, Meera, et al.
Publicado: (2020)

Infectious diseases, comorbidities and outcomes in hospitalized people who inject drugs (PWID) infections in persons who inject drugs
por: Lim, Jacqueline, et al.
Publicado: (2022)

1719. Pharmacokinetics (PK) of Oritavancin in Children: The ORKIDS Trial
por: Bradley, John, et al.
Publicado: (2018)

The Clinical Efficacy of Multidose Oritavancin: A Systematic Review
por: Baiardi, Giammarco, et al.
Publicado: (2023)

Brucella Endocarditis in Persons Who Inject Drugs
por: Cafardi, John M, et al.
Publicado: (2020)

Recurrent Endocarditis in Persons Who Inject Drugs
por: Rodger, Laura, et al.
Publicado: (2019)

Distinct Effectiveness of Oritavancin against Tolerance-Induced Staphylococcus aureus
por: Berti, Andrew D., et al.
Publicado: (2020)

Oritavancin polymethylmethacrylate (PMMA)—compressive strength testing and in vitro elution
por: Schmidt-Malan, Suzannah M., et al.
Publicado: (2019)

Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties
por: Hoover, Randall K, et al.
Publicado: (2022)

Infections with Spore-forming Bacteria in Persons Who Inject Drugs, 2000–2009
por: Palmateer, Norah E., et al.
Publicado: (2013)

Evaluation of Dalbavancin and Oritavancin as Cost-Effective Treatments of Acute Bacterial Skin and Skin Structure Infections in Hospitalized Patients
por: Koutsari, Christina, et al.
Publicado: (2017)

316. Hepatitis C and Engagement in Health Care Among Persons Who Inject Drugs and Persons Who Use Non-Injection Drugs, Philadelphia
por: Addish, Eman, et al.
Publicado: (2019)

Activity of Oritavancin and Its Synergy with Other Antibiotics against Mycobacterium abscessus Infection In Vitro and In Vivo
por: Wang, Gaoyan, et al.
Publicado: (2021)

Value of Packaged Testing for Sexually Transmitted Infections for Persons who Inject Drugs Hospitalized With Serious Injection-Related Infections
por: Marks, Laura R, et al.
Publicado: (2021)

A Two-Dose Oritavancin Regimen Using Pharmacokinetic Estimation Analysis
por: Rose, Warren E., et al.
Publicado: (2020)

1606. Distinct Effectiveness of Oritavancin Against Tolerance-Induced Staphylococcus aureus
por: Harven, Lauren, et al.
Publicado: (2020)

A Multistage Process Model of How a Person Who Currently Injects Drugs Comes to Assist Persons Who Do not Inject with Their First Injections
por: Des Jarlais, Don C., et al.
Publicado: (2021)

Severe Community-Acquired Bloodstream Infection with Acinetobacter ursingii in Person who Injects Drugs
por: Salzer, Helmut J.F., et al.
Publicado: (2016)

Bacterial and Fungal Infections in Persons Who Inject Drugs — Western New York, 2017
por: Hartnett, Kathleen P., et al.
Publicado: (2019)

1021. Repeat Infective Endocarditis (rIE) in Persons Who Inject Drugs (PWID)
por: Huang, Glen, et al.
Publicado: (2018)

114. Chorioretinal Lesions in Persons Who Inject Drugs and Are Hospitalized with Bloodstream and Related Infections
por: Greven, Margaret A, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_6kqj2ifqsbkvgsnr7g1g9tpo95